Published in Clin Cancer Res on January 26, 2010
Deficiency of activated STAT1 in head and neck cancer cells mediates TAP1-dependent escape from cytotoxic T lymphocytes. Cancer Immunol Immunother (2011) 1.11
A new hypothesis for the cancer mechanism. Cancer Metastasis Rev (2012) 1.03
Tumor-produced, active interleukin-1β regulates gene expression in carcinoma-associated fibroblasts. Exp Cell Res (2011) 0.99
microRNA-194 suppresses osteosarcoma cell proliferation and metastasis in vitro and in vivo by targeting CDH2 and IGF1R. Int J Oncol (2014) 0.97
Insulin-like growth factor 1 receptor (IGF1R) expression and survival in operable squamous-cell laryngeal cancer. PLoS One (2013) 0.95
Increased expression of interleukin-6 predicts poor response to chemoradiotherapy and unfavorable prognosis in oral squamous cell carcinoma. Oncol Rep (2015) 0.93
Prolactin receptor is a negative prognostic factor in patients with squamous cell carcinoma of the head and neck. Br J Cancer (2011) 0.86
Serum biomarker modulation following molecular targeting of epidermal growth factor and cyclooxygenase pathways: a pilot randomized trial in head and neck cancer. Oral Oncol (2012) 0.83
Opportunities and challenges facing biomarker development for personalized head and neck cancer treatment. Head Neck (2012) 0.83
The use of salivary cytokines as a screening tool for oral squamous cell carcinoma : A review of the literature. J Oral Maxillofac Pathol (2012) 0.82
Increased expression of the prolactin receptor is associated with malignant laryngeal tumors. Exp Ther Med (2012) 0.82
Transaminase Activity Predicts Survival in Patients with Head and Neck Cancer. PLoS One (2016) 0.80
Differential expression of the insulin-like growth factor receptor among early breast cancer subtypes. PLoS One (2014) 0.77
Molecular mechanisms of anti-tumor properties of P276-00 in head and neck squamous cell carcinoma. J Transl Med (2013) 0.77
Rapamycin targets Interleukin 6 (IL-6) expression and suppresses endothelial cell invasion stimulated by tumor cells. Am J Transl Res (2016) 0.75
Effects of definitive chemoradiation on circulating immunologic angiogenic cytokines in head and neck cancer patients. J Immunother Cancer (2016) 0.75
A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature (2008) 16.10
Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med (2014) 9.94
Probability of cancer in pulmonary nodules detected on first screening CT. N Engl J Med (2013) 4.64
Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N Engl J Med (2012) 3.52
Replication of lung cancer susceptibility loci at chromosomes 15q25, 5p15, and 6p21: a pooled analysis from the International Lung Cancer Consortium. J Natl Cancer Inst (2010) 3.18
XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol (2004) 2.93
Circulating 25-hydroxyvitamin D levels predict survival in early-stage non-small-cell lung cancer patients. J Clin Oncol (2007) 2.52
Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med (2008) 2.33
PSA screening and prostate cancer mortality. CMAJ (2002) 1.98
Group-size-mediated habitat selection and group fusion-fission dynamics of bison under predation risk. Ecology (2009) 1.98
Association between a 15q25 gene variant, smoking quantity and tobacco-related cancers among 17 000 individuals. Int J Epidemiol (2009) 1.97
VEGF polymorphisms and survival in early-stage non-small-cell lung cancer. J Clin Oncol (2008) 1.94
Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res (2004) 1.91
Bone turnover markers in the management of postmenopausal osteoporosis. Clin Biochem (2009) 1.85
Identification of cancer care and protocol characteristics associated with recruitment in breast cancer clinical trials. J Clin Oncol (2008) 1.83
Systematic review of the literature on characteristics of late-talking toddlers. Int J Lang Commun Disord (2008) 1.72
Health-related quality of life as a survival predictor for patients with localized head and neck cancer treated with radiation therapy. J Clin Oncol (2009) 1.70
A genome-wide association study identifies new susceptibility loci for esophageal adenocarcinoma and Barrett's esophagus. Nat Genet (2013) 1.67
Antihypertensive drug use and the risk of prostate cancer (Canada). Cancer Causes Control (2004) 1.63
Counterpoint: the myeloperoxidase -463G-->a polymorphism does not decrease lung cancer susceptibility in Caucasians. Cancer Epidemiol Biomarkers Prev (2002) 1.54
Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus. Nat Genet (2012) 1.52
Gene-environment interaction for the ERCC2 polymorphisms and cumulative cigarette smoking exposure in lung cancer. Cancer Res (2002) 1.45
The impact of germline genetic variations in hydroxysteroid (17-beta) dehydrogenases on prostate cancer outcomes after prostatectomy. Eur Urol (2011) 1.43
Circulating 25-hydroxyvitamin D, VDR polymorphisms, and survival in advanced non-small-cell lung cancer. J Clin Oncol (2008) 1.42
Gene-smoking interaction associations for the ERCC1 polymorphisms in the risk of lung cancer. Cancer Epidemiol Biomarkers Prev (2005) 1.38
Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients. Clin Cancer Res (2005) 1.36
Cannabis smoking and lung cancer risk: Pooled analysis in the International Lung Cancer Consortium. Int J Cancer (2014) 1.34
Genotypes and haplotypes of matrix metalloproteinase 1, 3 and 12 genes and the risk of lung cancer. Carcinogenesis (2005) 1.33
Combinations of the variant genotypes of GSTP1, GSTM1, and p53 are associated with an increased lung cancer risk. Cancer Res (2002) 1.33
Polymorphisms in the DNA repair genes XRCC1 and ERCC2, smoking, and lung cancer risk. Cancer Epidemiol Biomarkers Prev (2003) 1.33
Vitamin D is associated with improved survival in early-stage non-small cell lung cancer patients. Cancer Epidemiol Biomarkers Prev (2005) 1.33
Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation. J Natl Cancer Inst (2010) 1.30
Kernel machine SNP-set analysis for censored survival outcomes in genome-wide association studies. Genet Epidemiol (2011) 1.29
Previous lung diseases and lung cancer risk: a pooled analysis from the International Lung Cancer Consortium. Am J Epidemiol (2012) 1.27
A functional epidermal growth factor (EGF) polymorphism, EGF serum levels, and esophageal adenocarcinoma risk and outcome. Clin Cancer Res (2008) 1.27
Germline genetic contributions to risk for esophageal adenocarcinoma, Barrett's esophagus, and gastroesophageal reflux. J Natl Cancer Inst (2013) 1.25
Phase II study of preoperative gefitinib in clinical stage I non-small-cell lung cancer. J Clin Oncol (2009) 1.25
Polymorphisms of the NER pathway genes, ERCC1 and XPD are associated with esophageal adenocarcinoma risk. Cancer Causes Control (2008) 1.25
Vascular endothelial growth factor genotypes, haplotypes, gender, and the risk of non-small cell lung cancer. Clin Cancer Res (2008) 1.24
Soluble mesothelin-related Peptide and osteopontin as markers of response in malignant mesothelioma. J Clin Oncol (2010) 1.23
Effect of treatment delay on outcome of patients with early-stage head-and-neck carcinoma receiving radical radiotherapy. Int J Radiat Oncol Biol Phys (2002) 1.22
Inference methods for the conditional logistic regression model with longitudinal data. Biom J (2008) 1.20
Second hand smoke, age of exposure and lung cancer risk. Lung Cancer (2008) 1.19
Antioxidant vitamin and mineral supplementation and prostate cancer prevention in the SU.VI.MAX trial. Int J Cancer (2005) 1.19
Interaction between antioxidant vitamin supplementation and cigarette smoking during radiation therapy in relation to long-term effects on recurrence and mortality: a randomized trial among head and neck cancer patients. Int J Cancer (2008) 1.18
Genetic variations in esophageal cancer risk and prognosis. Gastroenterol Clin North Am (2009) 1.15
Apoptosis gene polymorphisms, age, smoking and the risk of non-small cell lung cancer. Carcinogenesis (2008) 1.15
MDM2 polymorphism, survival, and histology in early-stage non-small-cell lung cancer. J Clin Oncol (2007) 1.12
A Large-scale genetic association study of esophageal adenocarcinoma risk. Carcinogenesis (2010) 1.12
Germline genetic variation, cancer outcome, and pharmacogenetics. J Clin Oncol (2010) 1.12
Smoking cessation before diagnosis and survival in early stage non-small cell lung cancer patients. Lung Cancer (2006) 1.11
Polymorphisms of vitamin D receptor and survival in early-stage non-small cell lung cancer patients. Cancer Epidemiol Biomarkers Prev (2006) 1.10
Professional patient navigation in head and neck cancer. Semin Oncol Nurs (2009) 1.10
Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes. Pharmacogenet Genomics (2009) 1.09
Modeling lung cancer risk in case-control studies using a new dose metric of smoking. Cancer Epidemiol Biomarkers Prev (2005) 1.09
Genetic polymorphisms in N-acetyltransferase-2 and microsomal epoxide hydrolase, cumulative cigarette smoking, and lung cancer. Cancer Epidemiol Biomarkers Prev (2002) 1.06
Dosage, duration and timing of nonsteroidal antiinflammatory drug use and risk of prostate cancer. Int J Cancer (2003) 1.06
Matrix metalloproteinase 1, 3 and 12 polymorphisms and esophageal adenocarcinoma risk and prognosis. Carcinogenesis (2009) 1.06
Predictors of severe acute and late toxicities in patients with localized head-and-neck cancer treated with radiation therapy. Int J Radiat Oncol Biol Phys (2011) 1.04
Insulin-like growth factor binding protein 2: an androgen-dependent predictor of prostate cancer survival. Eur Urol (2005) 1.03
Predictors of weight loss during radiotherapy in patients with stage I or II head and neck cancer. Cancer (2010) 1.03
Genetic polymorphisms and head and neck cancer outcomes: a review. Cancer Epidemiol Biomarkers Prev (2008) 1.02
p53 and Ki-67 as markers of radioresistance in head and neck carcinoma. Cancer (2002) 1.02
Genetic polymorphisms of VEGF, interactions with cigarette smoking exposure and esophageal adenocarcinoma risk. Carcinogenesis (2008) 1.01
Risk of pancreatic cancer among individuals with a family history of cancer of the pancreas. Int J Cancer (2002) 1.01
MDM2 promoter polymorphism and pancreatic cancer risk and prognosis. Clin Cancer Res (2008) 1.01
Implementing the role of patient-navigator nurse at a university hospital centre. Can Oncol Nurs J (2006) 1.00
Role of immunohistochemical overexpression of matrix metalloproteinases MMP-2 and MMP-11 in the prognosis of death by ovarian cancer. Am J Clin Pathol (2008) 1.00
Genetic polymorphisms as predictive and prognostic biomarkers in gynecological cancers: a systematic review. Gynecol Oncol (2011) 1.00
Comparison of pathway analysis approaches using lung cancer GWAS data sets. PLoS One (2012) 1.00
Myeloperoxidase and superoxide dismutase polymorphisms are associated with an increased risk of developing pancreatic adenocarcinoma. Cancer (2008) 0.99
Dietary iron, zinc, and calcium and the risk of lung cancer. Epidemiology (2005) 0.98
Treatment of the elderly when cure is the goal: the influence of age on treatment selection and efficacy for stage III non-small cell lung cancer. J Thorac Oncol (2011) 0.98
Impact and feasibility of a comprehensive geriatric assessment in the oncology setting: a pilot study. Am J Clin Oncol (2012) 0.98
Vascular endothelial growth factor polymorphisms and esophageal cancer prognosis. Clin Cancer Res (2009) 0.97
Prognostic factors for cure, recurrence and long-term survival after surgical resection of thymoma. J Thorac Oncol (2014) 0.96
Association between UGT1A1*28 polymorphisms and clinical outcomes of irinotecan-based chemotherapies in colorectal cancer: a meta-analysis in Caucasians. PLoS One (2013) 0.96
p53 Arg72Pro and MDM2 T309G polymorphisms, histology, and esophageal cancer prognosis. Clin Cancer Res (2009) 0.96
Prognostic significance of lymphovascular invasion in surgically cured rectal carcinoma. Am J Surg (2005) 0.95
p53 Arg72Pro polymorphism, HPV status and initiation, progression, and development of cervical cancer: a systematic review and meta-analysis. Clin Cancer Res (2012) 0.95
Eye care utilization by older adults in low, middle, and high income countries. BMC Ophthalmol (2012) 0.95
Problems with the estimation of urine protein by automated assays. Clin Biochem (2005) 0.94
Matrix metalloproteinase-1 promoter polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev (2005) 0.94
Cancer patients acceptance, understanding, and willingness-to-pay for pharmacogenomic testing. Pharmacogenet Genomics (2014) 0.93
Lack of correlation between a self-administered subjective GERD questionnaire and pathologic GERD diagnosed by 24-h esophageal pH monitoring. J Gastrointest Surg (2010) 0.92
Interactions among genetic variants in apoptosis pathway genes, reflux symptoms, body mass index, and smoking indicate two distinct etiologic patterns of esophageal adenocarcinoma. J Clin Oncol (2010) 0.92
A prospective study of the insulin-like growth factor axis in relation with prostate cancer in the SU.VI.MAX trial. Cancer Epidemiol Biomarkers Prev (2005) 0.92
Dietary vitamin D intake and serum 25-hydroxyvitamin D level in relation to disease outcomes in head and neck cancer patients. Int J Cancer (2010) 0.92
Comorbidity and prognosis in head and neck cancers: Differences by subsite, stage, and human papillomavirus status. Head Neck (2013) 0.91
Genetic variations as cancer prognostic markers: review and update. Hum Mutat (2009) 0.91
Primary tumor xenografts of human lung adeno and squamous cell carcinoma express distinct proteomic signatures. J Proteome Res (2010) 0.91